ImageneBio, Inc. (IMA) - Total Assets
Based on the latest financial reports, ImageneBio, Inc. (IMA) holds total assets worth $152.98 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See ImageneBio, Inc. book value and equity for net asset value and shareholders' equity analysis.
ImageneBio, Inc. - Total Assets Trend (2018–2025)
This chart illustrates how ImageneBio, Inc.'s total assets have evolved over time, based on quarterly financial data.
ImageneBio, Inc. - Asset Composition Analysis
Current Asset Composition (December 2025)
ImageneBio, Inc.'s total assets of $152.98 Million consist of 91.7% current assets and 8.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 22.9% |
| Accounts Receivable | $1.30 Million | 0.9% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how ImageneBio, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of ImageneBio, Inc..
Key Asset Composition Facts
- Current vs. Non-Current Assets: ImageneBio, Inc.'s current assets represent 91.7% of total assets in 2025, a decrease from 96.6% in 2018.
- Cash Position: Cash and equivalents constituted 22.9% of total assets in 2025, down from 87.8% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 0.9% of total assets.
ImageneBio, Inc. Competitors by Total Assets
Key competitors of ImageneBio, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
ImageneBio, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 12.49 | 11.80 | 9.44 |
| Quick Ratio | 12.49 | 11.80 | 9.44 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $129.05 Million | $116.39 Million | $253.22 Million |
ImageneBio, Inc. - Advanced Valuation Insights
This section examines the relationship between ImageneBio, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.40 |
| Latest Market Cap to Assets Ratio | 0.35 |
| Asset Growth Rate (YoY) | 8.1% |
| Total Assets | $152.98 Million |
| Market Capitalization | $53.13 Million USD |
Valuation Analysis
Below Book Valuation: The market values ImageneBio, Inc.'s assets below their book value (0.35x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: ImageneBio, Inc.'s assets grew by 8.1% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for ImageneBio, Inc. (2018–2025)
The table below shows the annual total assets of ImageneBio, Inc. from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $152.98 Million | +8.10% |
| 2024-12-31 | $141.51 Million | -26.33% |
| 2023-12-31 | $192.09 Million | +11.51% |
| 2022-12-31 | $172.26 Million | -30.51% |
| 2021-12-31 | $247.88 Million | +47.19% |
| 2020-12-31 | $168.40 Million | +95.88% |
| 2019-12-31 | $85.97 Million | +315.82% |
| 2018-12-31 | $20.68 Million | -- |
About ImageneBio, Inc.
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerl… Read more